Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.67 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.67 |
| ▸ | PKM | P14618 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.58 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231897 | 0.87 | KDR (0.78) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL29184186 | 0.85 | KDR (0.76) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL7988912 | 0.84 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL18993402 | 0.84 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL6037587 | 0.84 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL10415452 | 0.84 | GRM4 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL6037590 | 0.84 | KDR (0.78) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL30686047 | 0.84 | GRM4 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL20990144 | 0.84 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL3099628 | 0.84 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263772-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION | NEUMENTUM INC (US) | 2023-08-24 | — | — | US | claimed |
| CN-113993846-A | Compositions and methods for treating pain and/or inflammation | 诺门图姆股份有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-20230263772-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION | NEUMENTUM INC (US) | 2023-08-24 | — | — | US | disclosed |
| CN-114591185-B | Method for selectively preparing alkamine from ethylene glycol and nitroarene | 大连理工大学 | 2023-02-14 | — | — | CN | disclosed |
| CN-114591185-A | Method for selectively preparing alkamine from ethylene glycol and nitroarene | 大连理工大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-113993846-A | Compositions and methods for treating pain and/or inflammation | 诺门图姆股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263772-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION | ADORA3, P2RX3, ADORA2A | NPC1 4847/4885RAB9A 3135/4885SMN1; SMN2 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.